Research

Preclinical immunology, run with clinical discipline

Three programmes, each with defined endpoints and honest stage labels. CAR-T is our most active line of work today, but it is one strand of the thesis rather than the whole of it. Nothing below describes an approved therapy or an active clinical trial.

View the ongoing CAR-T programme

Programme 01

CAR-T Cell Therapy

Active — discovery / preclinical

Our most active line of work, though not the whole of our research. We investigate chimeric antigen receptor architectures adapted from oncology for use in severe autoimmune disease, where the target is a pathogenic B-cell or T-cell population rather than a tumour. The full workstream breakdown, methods and endpoints live on the ongoing research page.

Cell engineering research

Construct design, transduction efficiency, and vector-free delivery approaches evaluated across donor-derived primary cells.

Safety and tolerability studies

Cytokine release characterisation, on-target/off-tumour modelling, and engineered kill-switch evaluation in vitro.

Mechanism investigation

Single-cell readouts of expansion, exhaustion and memory phenotype to explain why a construct behaves as it does.

Programme 02

Precision Diagnostics

Assay development

Therapy decisions are only as good as the immune picture behind them. We build high-dimensional profiling assays that describe a patient's immune state with enough resolution to stratify who might respond to a given intervention.

Immune profiling

Multi-parameter cytometry and transcriptional panels covering innate and adaptive compartments.

Biomarker discovery

Candidate markers of immune dysfunction validated across independent sample cohorts.

Patient stratification

Statistical models that group patients by mechanism rather than by symptom label alone.

Programme 03

Immune Restoration

Exploratory

For patients whose immune systems are depleted by disease or treatment, restoration is the goal rather than suppression. This programme studies how compromised compartments recover, and what can be done to accelerate that recovery safely.

Cell regeneration

Ex vivo expansion protocols for depleted lymphocyte populations.

Function recovery

Functional assays that measure restored response, not just restored cell counts.

Immune enhancement

Adjunct strategies evaluated for durability and autoimmune risk.

Scientific standards

How we hold ourselves to account

01
Study designs are documented before data collection begins.
02
Every key result is reproduced with an orthogonal method.
03
Negative and null results are recorded and retained.
04
External collaborators receive raw data, not only summaries.

Researcher examining samples through a fluorescence microscope, viewed from behind

Method in practice

Every experiment is run by people who read the raw data first

Our team works directly with the instruments, the cells and the datasets. There is no wall between the scientist designing the study and the scientist validating the result.

That closeness is what lets us catch subtle signals early, and what keeps our stage labels honest.

Interested in co-authoring one of these programmes?

Explore partnerships